Argyris Tzouvelekis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2582606/publications.pdf

Version: 2024-02-01

43 1,448 18 papers citations h-index

43 43 43 2151 all docs docs citations times ranked citing authors

37

g-index

#	Article	IF	CITATIONS
1	A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. Journal of Translational Medicine, 2013, 11, 171.	4.4	209
2	Comparative Expression Profiling in Pulmonary Fibrosis Suggests a Role of Hypoxia-inducible Factor-1α in Disease Pathogenesis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1108-1119.	5 . 6	178
3	Lung cancer in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2017, 45, 1-10.	2.6	129
4	Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer. Chest, 2019, 156, 383-391.	0.8	84
5	Serum biomarkers in interstitial lung diseases. Respiratory Research, 2005, 6, 78.	3.6	69
6	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine, the, 2018, 6, 86-88.	10.7	67
7	Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 55, 17-24.	2.6	62
8	Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. Journal of Translational Medicine, 2011, 9, 182.	4.4	61
9	Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis. Pulmonary Medicine, 2012, 2012, 1-7.	1.9	56
10	Stem cell therapy in pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 368-373.	2.6	49
11	Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulmonary Medicine, 2013, 13, 31.	2.0	44
12	Increased Expression of Epidermal Growth Factor Receptor (EGF-R) in Patients with Different Forms of Lung Fibrosis. BioMed Research International, 2013, 2013, 1-11.	1.9	43
13	Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander?. Respiratory Research, 2006, 7, 82.	3.6	42
14	Stem Cell Treatment for Chronic Lung Diseases. Respiration, 2013, 85, 179-192.	2.6	35
15	Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101880.	2.6	31
16	Serum biomarkers in Acute Respiratory Distress Syndrome an ailing prognosticator. Respiratory Research, 2005, 6, 62.	3.6	28
17	Acute fibrinous and organising pneumonia: a case report and review of the literature. Journal of Medical Case Reports, 2009, 3, 74.	0.8	27
18	Expression of Hypoxia-Inducible Factor (HIF)-1a-Vascular Endothelial Growth Factor (VEGF)-Inhibitory Growth Factor (ING)-4- axis in sarcoidosis patients. BMC Research Notes, 2012, 5, 654.	1.4	26

#	Article	IF	Citations
19	Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient's "Q and A― approach. Pulmonary Pharmacology and Therapeutics, 2017, 42, 21-24.	2.6	18
20	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2020, 7, 29.	2.6	18
21	Application of microarray technology in pulmonary diseases. Respiratory Research, 2004, 5, 26.	3.6	15
22	Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respiratory Research, 2009, 10, 14.	3.6	15
23	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Research, 2020, 6, 00152-2020.	2.6	15
24	Idiopathic Pulmonary Hemosiderosis in Adults: A Case Report and Review of the Literature. Case Reports in Medicine, 2012, 2012, 1-5.	0.7	14
25	Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice― Frontiers in Medicine, 2017, 4, 151.	2.6	14
26	Stem Cell Therapy in Chronic Obstructive Pulmonary Disease. Seeking the Prometheus Effect. Current Drug Targets, 2013, 14, 246-252.	2.1	14
27	Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis. Pulmonary Medicine, 2011, 2011, 1-7.	1.9	11
28	Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine, the, 2018, 6, 82-84.	10.7	10
29	Anti-acid treatment for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine, the, 2013, 1, 348-349.	10.7	8
30	Pirfenidone in the kaleidoscope: reflecting mechanisms through differentÂangles. European Respiratory Journal, 2018, 52, 1802046.	6.7	8
31	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	4.1	8
32	Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease. Clinics in Chest Medicine, 2019, 40, 679-691.	2.1	7
33	Hypersensitivity pneumonitis: the first diagnostic guidelines. Lancet Respiratory Medicine,the, 2020, 8, 955-957.	10.7	7
34	Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. Current Opinion in Pharmacology, 2021, 57, 71-80.	3.5	7
35	A role of antifibrotics in the treatment of Scleroderma-ILD?. Pulmonology, 2020, 26, 1-2.	2.1	5
36	Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World― Respiration, 2017, 94, 405-407.	2.6	4

#	Article	IF	CITATION
37	Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey. EBioMedicine, 2020, 51, 102591.	6.1	3
38	The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity. Frontiers in Medicine, 2020, 7, 176.	2.6	3
39	Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what'sÂin a name?. European Respiratory Journal, 2019, 53, 1800994.	6.7	2
40	Post-intubation pulmonary embolism and tracheal stenosis: A case report and review of the literature. Respiratory Medicine, 2008, 102, 1208-1212.	2.9	1
41	Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis: Thinking Outside the Box in Disease Management and Prognostication. Respiration, 2017, 94, 334-335.	2.6	1
42	Dissecting Survival Pathways in Lung Cancer, Fibrosis and Emphysema: "The Four Horses of the Apocalypse― Respiration, 2017, 94, 239-241.	2.6	0
43	Embryonic stem cells for lung fibrosis Is it the Prometheus myth or the Pandora's Box?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2013, 30, 246-8.	0.2	0